Literature DB >> 14623030

Suppressive effects of Active Hexose Correlated Compound on the increased activity of hepatic and renal ornithine decarboxylase induced by oxidative stress.

She-Fang Ye1, Kaoru Ichimura, Koji Wakame, Masato Ohe.   

Abstract

Active Hexose Correlated Compound (AHCC), an extract derived from fungi of Basidiomycetes family has been shown to act as a biological response modifier in various disorders. In our present study, ferric nitrilotriacetate (Fe-NTA), which generates hydroxyl radicals in vivo, was given intraperitoneally to rats and AHCC was tested for its ability to suppress oxidative stress and the activity of ornithine decarboxylase (ODC) in the liver and kidney. Substantial increments in glutathione-related enzymes including glutathione reductase, glutathione peroxidase activity as well as oxidized glutathione contents were shown in the liver at 12 h after treatment with Fe-NTA (7.5 mg Fe/kg body weight). Effects of oxidative stress induced by Fe-NTA were also demonstrated by the increase in serum lipid peroxidation, aminotransferases and urinary 8-hydroxy-2'-deoxyguanosine. However, the increases in these parameters were restored to normal in AHCC-pretreated rats. The ODC activity in the liver and kidney was significantly increased by Fe-NTA, while the increased ODC activity induced by Fe-NTA was normalized in AHCC-pretreated rats. These results suggest AHCC acts as a potent antioxidant and protects against disorders induced by oxidative stresses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14623030     DOI: 10.1016/j.lfs.2003.06.038

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  7 in total

1.  Practical Application of "About Herbs" Website: Herbs and Dietary Supplement Use in Oncology Settings.

Authors:  Yen-Nien Hou; Gary Deng; Jun J Mao
Journal:  Cancer J       Date:  2019 Sep/Oct       Impact factor: 3.360

2.  Active Holistic Surveillance: The Nutritional Aspect of Delayed Intervention in Prostate Cancer.

Authors:  Courtney J Berg; David J Habibian; Aaron E Katz; Kaitlin E Kosinski; Anthony T Corcoran; Andrew S Fontes
Journal:  J Nutr Metab       Date:  2016-05-05

3.  Bioactive Immunomodulatory Compounds: A Novel Combinatorial Strategy for Integrated Medicine in Oncology? BAIC Exposure in Cancer Cells.

Authors:  Bruna Corradetti; Salvatore Vaiasicca; Mauro Mantovani; Edy Virgili; Massimo Bonucci; Ivano Hammarberg Ferri
Journal:  Integr Cancer Ther       Date:  2019 Jan-Dec       Impact factor: 3.279

4.  Efficacy of active hexose correlated compound on survival of patients with resectable/borderline resectable pancreatic cancer: a study protocol for a double-blind randomized phase II study.

Authors:  Daisuke Hashimoto; Sohei Satoi; Hideki Ishikawa; Yasuhiro Kodera; Keiko Kamei; Satoshi Hirano; Tsutomu Fujii; Kenichiro Uemura; Akihiko Tsuchida; Suguru Yamada; Tomohisa Yamamoto; Kiichi Hirota; Mitsugu Sekimoto
Journal:  Trials       Date:  2022-02-12       Impact factor: 2.279

5.  A Standardized Extract of Lentinula edodes Cultured Mycelium Inhibits Pseudomonas aeruginosa Infectivity Mechanisms.

Authors:  Mireia Tena-Garitaonaindia; Diego Ceacero-Heras; María Del Mar Maldonado Montoro; Fermín Sánchez de Medina; Olga Martínez-Augustin; Abdelali Daddaoua
Journal:  Front Microbiol       Date:  2022-03-16       Impact factor: 5.640

6.  The Combination of AHCC and ETAS Decreases Migration of Colorectal Cancer Cells, and Reduces the Expression of LGR5 and Notch1 Genes in Cancer Stem Cells: A Novel Potential Approach for Integrative Medicine.

Authors:  Francesca Paganelli; Francesca Chiarini; Annalisa Palmieri; Marcella Martinelli; Paola Sena; Jessika Bertacchini; Luca Roncucci; Alessandra Cappellini; Alberto M Martelli; Massimo Bonucci; Carla Fiorentini; Ivano Hammarberg Ferri
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-18

7.  Effects of AHCC® on Immune and Stress Responses in Healthy Individuals.

Authors:  Jun Takanari; Atsuya Sato; Hideaki Waki; Shogo Miyazaki; Kazuo Uebaba; Tatsuya Hisajima
Journal:  J Evid Based Integr Med       Date:  2018 Jan-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.